TSX News -
Swiss Water Reports Third Quarter and Year-to-Date Results
Volumes up by 12% for the first nine months of 2018, together with third quarter margin enhancement A conference call […]
Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China
– 50/50 joint venture with investor syndicate led by Vivo Capital – – Expands global reach for TransCon products – […]
Franklin Resources, Inc. Announces Month-End Assets Under Management
SAN MATEO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) — Franklin Resources, Inc. (Franklin Templeton Investments) (NYSE: BEN) today reported preliminary […]
WillScot Announces Commencement of Exchange Offer Relating to Its Warrants
BALTIMORE, Nov. 08, 2018 (GLOBE NEWSWIRE) — WillScot Corporation (“WillScot”) (NASDAQ: WSC), the specialty rental services market leader providing innovative […]
U.S. Global Investors Reports Financial Results for the First Quarter of 2019 Fiscal Year
SAN ANTONIO, Nov. 08, 2018 (GLOBE NEWSWIRE) — U.S. Global Investors, Inc. (NASDAQ: GROW) (the “Company”), a boutique registered investment […]
TSX News -
Acquisition of Shares of Maritime Resources Corp.
TORONTO, Nov. 08, 2018 (GLOBE NEWSWIRE) — In accordance with regulatory requirements, Dundee Corporation (TSX: DC.A) (“Dundee”) announces that its […]
Gladstone Land Announces Third Quarter 2018 Results
MCLEAN, Va., Nov. 08, 2018 (GLOBE NEWSWIRE) — Gladstone Land Corporation (Nasdaq: LAND) (“Gladstone Land” or the “Company”) today reported […]
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2018 Financial Results
Company Executing on Lead Programs CPI-1205 and CPI-0610 Expects to Evaluate Proof of Concept for Both Programs in Mid-2019 CAMBRIDGE, Mass., […]
Exela Technologies, Inc. Reports Third Quarter 2018 Results
Revenue of $383.0 million an increase of 7% over Q3 2017 on a pro forma basis; Net Loss of $28.9 […]
Intellia Therapeutics to Present at November Healthcare Investor Conferences
CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing […]
